JAMONY
NKTR icon

Jacob Asset Management of New York’s Nektar Therapeutics NKTR Stock Holding History

Jacob Asset Management of New York’s Portfolio NKTR Stock Details NKTR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2013
Q3 		$334K Hold
2,133
– – 0.41% 73
2013
Q2 		$370K Buy
+2,133
New +$327K 0.5% 60

Other funds holding NKTR

O
OppenheimerFunds New York $80.4B AUM 17.47% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.14% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.26% 1-Year Est. Return
First Trust Advisors
First Trust Advisors Wheaton, Illinois $140B AUM 27.84% 1-Year Est. Return
GIM
Granahan Investment Management Waltham, Massachusetts $2.07B AUM 56.45% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return

Jacob Asset Management of New York's NKTR Position: Q3 2013 in Review

Jacob Asset Management of New York held its Nektar Therapeutics (NKTR) position steady in Q3 2013 at 2,133 shares worth $334K. The position accounts for 0.41% of the portfolio, ranked #73.

Jacob Asset Management of New York first reported a position in NKTR in Q2 2013 and has held it in 2 quarters since. The position peaked at $370K in Q2 2013. 142 funds tracked by Wall St. Rank hold NKTR as of Q3 2013.

  • Jacob Asset Management of New York held 2,133 shares of Nektar Therapeutics worth $334K as of Q3 2013.
  • Jacob Asset Management of New York left its Nektar Therapeutics share count unchanged in Q3 2013.
  • Nektar Therapeutics made up 0.41% of Jacob Asset Management of New York's portfolio in Q3 2013, its #73 holding.
  • Jacob Asset Management of New York first reported a position in Nektar Therapeutics in Q2 2013 and has held it in 2 quarters since.
  • Jacob Asset Management of New York's Nektar Therapeutics position peaked at $370K in Q2 2013.
  • 142 funds tracked by Wall St. Rank held Nektar Therapeutics as of Q3 2013.

Based on Jacob Asset Management of New York's 13F filing for Q3 2013, filed 14 Nov 2013.